Study of a new drug for advanced neuroendocrine prostate cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Kidney & urinary clinical trials.
This trial tests a new drug (ZG006) for men with advanced neuroendocrine prostate cancer that has progressed after standard platinum-based chemotherapy. The goal is to see if the drug can help slow or shrink the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man between the ages of 18 and 80.
- You have advanced prostate cancer that has spread and has a certain type called neuroendocrine (which is a more aggressive form).
- You have already received at least one line of platinum-based chemotherapy (like cisplatin or carboplatin), and the cancer either kept growing or you had to stop due to side effects.
- You have at least one tumor that can be measured on a scan (CT or MRI).
- You are generally active and able to care for yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ZG006 for people with advanced small cell lung cancer or a type of neuroendocrine cancer. It aims to find the best dose and see if it helps shrink tumors.
This trial is testing a new drug called ZG006 for people with advanced small cell lung cancer or neuroendocrine carcinoma. The study has two parts: first finding the right dose, then testing it in more people with neuroendocrine carcinoma.
This study tests a new investigational drug called ZG006 against the chemotherapy your doctor would normally choose for advanced neuroendocrine carcinoma. The trial aims to see if ZG006 works better than standard chemotherapy for people whose cancer has progressed after earlier treatment.
This trial tests two new drugs, ZG006 and ZG005, for people with advanced small cell lung cancer or neuroendocrine carcinoma. The goal is to see if these drugs can shrink tumors or slow cancer growth.
This trial tests a new drug combination (GZ17-6.02) for men with advanced prostate cancer that has stopped responding to standard hormone therapies. The goal is to see if the drug can help slow down the cancer.
This trial tests whether adding a new drug, ZG005, to standard chemotherapy (etoposide and cisplatin) is better than the chemotherapy alone for treating advanced neuroendocrine carcinoma that has not been treated before. The study aims to see if the combination can help people live longer or slow the cancer's growth.
Hear when a new Neuroendocrine Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.